ATE311889T1 - Kombination aus beta-2-adrenozeptor-agonisten und aminozuckern und ihre verwendung zur behandlung von immunmodulatorischen erkrankungen - Google Patents
Kombination aus beta-2-adrenozeptor-agonisten und aminozuckern und ihre verwendung zur behandlung von immunmodulatorischen erkrankungenInfo
- Publication number
- ATE311889T1 ATE311889T1 AT03752710T AT03752710T ATE311889T1 AT E311889 T1 ATE311889 T1 AT E311889T1 AT 03752710 T AT03752710 T AT 03752710T AT 03752710 T AT03752710 T AT 03752710T AT E311889 T1 ATE311889 T1 AT E311889T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- treatment
- adrenoceptor agonist
- amino sugar
- sugar combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37361502P | 2002-04-19 | 2002-04-19 | |
DKPA200200586 | 2002-04-19 | ||
PCT/DK2003/000263 WO2003097073A1 (en) | 2002-04-19 | 2003-04-22 | Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE311889T1 true ATE311889T1 (de) | 2005-12-15 |
Family
ID=49447268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03752710T ATE311889T1 (de) | 2002-04-19 | 2003-04-22 | Kombination aus beta-2-adrenozeptor-agonisten und aminozuckern und ihre verwendung zur behandlung von immunmodulatorischen erkrankungen |
Country Status (18)
Country | Link |
---|---|
US (1) | US20050130935A1 (de) |
EP (2) | EP1496917B1 (de) |
JP (1) | JP2005529151A (de) |
KR (1) | KR20050007460A (de) |
CN (1) | CN1646143A (de) |
AT (1) | ATE311889T1 (de) |
AU (1) | AU2003260279B2 (de) |
CA (1) | CA2482746A1 (de) |
DE (1) | DE60308915T2 (de) |
DK (1) | DK1496917T3 (de) |
EA (1) | EA007906B1 (de) |
ES (1) | ES2254960T3 (de) |
HK (1) | HK1073436A1 (de) |
NO (1) | NO20045038L (de) |
NZ (1) | NZ536447A (de) |
PL (1) | PL373190A1 (de) |
SI (1) | SI1496917T1 (de) |
WO (1) | WO2003097073A1 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004028468A2 (en) | 2002-09-27 | 2004-04-08 | Children's Medical Center Corporation | Methods and compositions for treatment of neurological disorder |
US20070179181A1 (en) * | 2004-03-17 | 2007-08-02 | Baxter Andrew D | Treatment of inflammatory disorders and pain using beta-aminoalcohols |
US8426475B2 (en) * | 2005-04-13 | 2013-04-23 | Astion Development A/S | Treatment of connective tissue diseases of the skin |
US9877921B2 (en) | 2005-09-09 | 2018-01-30 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
TW200800142A (en) * | 2005-09-09 | 2008-01-01 | Univ Manitoba | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
US20160045457A1 (en) | 2005-09-09 | 2016-02-18 | Ousama Rachid | Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
GB0604826D0 (en) * | 2006-03-09 | 2006-04-19 | Arakis Ltd | The treatment of inflammatory disorders and pain |
TW200817049A (en) * | 2006-06-05 | 2008-04-16 | Verus Pharmaceuticals Inc | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
US20070293581A1 (en) * | 2006-06-05 | 2007-12-20 | Malcolm Hill | Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies |
GB0625270D0 (en) * | 2006-12-19 | 2007-01-31 | Univ Leicester | Angiogenesis |
CA2903133C (en) * | 2007-05-31 | 2021-10-19 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | N-acetyl mannosamine or derivatives thereof for use in treating a kidney disorder in a mammal |
GB0805535D0 (en) | 2008-03-27 | 2008-04-30 | Univ Leicester | Scar prevention |
US20110097401A1 (en) | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
US20120322884A1 (en) | 2010-03-01 | 2012-12-20 | University Of Manitoba | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
JP2013523764A (ja) | 2010-03-30 | 2013-06-17 | アルジーノミクス インコーポレイテッド | 体性感覚障害治療用の組成物と方法 |
US8716350B2 (en) | 2010-03-30 | 2014-05-06 | Algynomics Inc. | Compositions and methods for the treatment of somatosensory disorders |
CA2853084C (en) | 2011-10-21 | 2022-04-26 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
CA2876883C (en) | 2012-06-15 | 2022-11-01 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
GB2513297A (en) | 2013-03-08 | 2014-10-29 | Univ Leicester | Methods |
HUE055773T2 (hu) | 2013-03-22 | 2021-12-28 | Univ Nova Southeastern | Epinefrin finom részecskék és módszerek azok alkalmazására az epinefrinre reagáló állapotok kezelésében |
CN105601685B (zh) * | 2016-01-08 | 2017-12-26 | 鲁东大学 | 含喹唑啉环壳寡糖衍生物及制备方法和生物活性 |
WO2018000098A1 (en) * | 2016-06-30 | 2018-01-04 | Cipher Pharmaceuticals Inc. | Treatment of inflammatory myopathies |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4647453A (en) * | 1984-10-18 | 1987-03-03 | Peritain, Ltd. | Treatment for tissue degenerative inflammatory disease |
JP3390477B2 (ja) * | 1993-01-25 | 2003-03-24 | 生化学工業株式会社 | 薬剤組成物及びその製造法 |
AU1533495A (en) * | 1994-01-12 | 1995-08-01 | Byk Nederland Bv | Phenyl ethanol amine ethers and uses thereof as beta-adreno-receptor agonists |
US6255295B1 (en) * | 1996-12-23 | 2001-07-03 | Nutramax Laboratories, Inc. | Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue |
US6046179A (en) * | 1998-04-17 | 2000-04-04 | Murch; Simon | Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine |
US20020136782A1 (en) * | 2001-01-18 | 2002-09-26 | Fleischner Albert M. | Composition patent for solid-dosage form of weight loss product |
US6420350B1 (en) * | 2001-01-18 | 2002-07-16 | Goen Group, Inc. | Weight loss product |
-
2003
- 2003-04-22 AT AT03752710T patent/ATE311889T1/de not_active IP Right Cessation
- 2003-04-22 ES ES03752710T patent/ES2254960T3/es not_active Expired - Lifetime
- 2003-04-22 EP EP03752710A patent/EP1496917B1/de not_active Expired - Lifetime
- 2003-04-22 KR KR10-2004-7016710A patent/KR20050007460A/ko not_active Application Discontinuation
- 2003-04-22 CA CA002482746A patent/CA2482746A1/en not_active Abandoned
- 2003-04-22 EA EA200401404A patent/EA007906B1/ru not_active IP Right Cessation
- 2003-04-22 NZ NZ536447A patent/NZ536447A/en unknown
- 2003-04-22 US US10/512,029 patent/US20050130935A1/en not_active Abandoned
- 2003-04-22 JP JP2004505071A patent/JP2005529151A/ja active Pending
- 2003-04-22 CN CNA038087146A patent/CN1646143A/zh active Pending
- 2003-04-22 WO PCT/DK2003/000263 patent/WO2003097073A1/en active IP Right Grant
- 2003-04-22 AU AU2003260279A patent/AU2003260279B2/en not_active Expired - Fee Related
- 2003-04-22 EP EP05013726A patent/EP1642574A3/de not_active Withdrawn
- 2003-04-22 DE DE60308915T patent/DE60308915T2/de not_active Expired - Fee Related
- 2003-04-22 DK DK03752710T patent/DK1496917T3/da active
- 2003-04-22 PL PL03373190A patent/PL373190A1/xx not_active Application Discontinuation
- 2003-04-22 SI SI200330173T patent/SI1496917T1/sl unknown
-
2004
- 2004-11-19 NO NO20045038A patent/NO20045038L/no not_active Application Discontinuation
-
2005
- 2005-07-06 HK HK05105654A patent/HK1073436A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2005529151A (ja) | 2005-09-29 |
KR20050007460A (ko) | 2005-01-18 |
EP1496917A1 (de) | 2005-01-19 |
EA200401404A1 (ru) | 2005-04-28 |
DK1496917T3 (da) | 2006-04-10 |
DE60308915T2 (de) | 2006-12-21 |
EA007906B1 (ru) | 2007-02-27 |
DE60308915D1 (de) | 2006-11-16 |
AU2003260279B2 (en) | 2008-01-24 |
AU2003260279A1 (en) | 2003-12-02 |
EP1496917B1 (de) | 2005-12-07 |
ES2254960T3 (es) | 2006-06-16 |
SI1496917T1 (sl) | 2006-06-30 |
CA2482746A1 (en) | 2003-11-27 |
EP1642574A3 (de) | 2008-11-12 |
CN1646143A (zh) | 2005-07-27 |
PL373190A1 (en) | 2005-08-22 |
NZ536447A (en) | 2006-05-26 |
WO2003097073A1 (en) | 2003-11-27 |
EP1642574A2 (de) | 2006-04-05 |
US20050130935A1 (en) | 2005-06-16 |
NO20045038L (no) | 2004-11-19 |
HK1073436A1 (en) | 2005-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE311889T1 (de) | Kombination aus beta-2-adrenozeptor-agonisten und aminozuckern und ihre verwendung zur behandlung von immunmodulatorischen erkrankungen | |
EP2497478A3 (de) | Oligosaccarid-Zusammensetzungen und ihre Verwendung bei der Behandlung von Infektionen | |
ES2166820T3 (es) | Sustancias activas o combinaciones de sustancias activas y preparados contra el envejecimiento de la piel. | |
DE60237431D1 (de) | Rezeptor-selektive cannabimimetische aminoalkylindole | |
RU2008103480A (ru) | Средство, содержащее l-карнитин или производные l-карнитина и, по меньшей мере, одно определенное другое вещество | |
WO2003099195A3 (en) | Immunomodulatory compounds and methods of use thereof | |
IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
ATE389649T1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
CA2547445A1 (en) | Systems and methods for altering vestibular biology | |
ATE462427T1 (de) | Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren | |
ATE390142T1 (de) | Synergistische zusammensetzung zur behandlung von diabetes mellitus | |
WO2005023185A3 (en) | Pharmaceutical compositions and method of using levodopa and carbidopa | |
ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
EA200870088A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов и глюкозы в крови | |
ATE315390T1 (de) | Zyklische polyamine zur behandlung der thrombozytopenie | |
BRPI0415179A (pt) | derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas | |
BR0313239A (pt) | Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças | |
DE60335647D1 (de) | Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden | |
PT1572178E (pt) | Tratamento de mastalgia com 4-hidroxi-tamoxifeno | |
DE60230455D1 (de) | Natürliche verbindung für die behandlung von diabetes, deren herstellung und verwendung | |
WO2004056768A3 (en) | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | |
EP1546377A4 (de) | Verfahren und zusammensetzungen zur behandlung von schmerzen und schmerzhaften erkrankungen unter verwendung von 9949, 14230, 760, 62553, 41897, 47174, 33408, 10002,16209, 314, 636, 27410, 33260, 619,15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 9569 oder 13424 molekülen | |
ATE375152T1 (de) | Behandlung von gastrointestinalen erkrankungen mit n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2- amine | |
ATE453386T1 (de) | Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten | |
AU2003290970A1 (en) | Compositions and method for treating affective, painful or allergic disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1496917 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |